Caris Life Sciences vs Sectra Pathology
A treating oncologist orders MI Cancer Seek on FFPE tissue from Caris, which was founded in 2008 and trades on NASDAQ as CAI. The companion diagnostic claims cover drugs such as Vectibix (KRAS/NRAS wild-type), Braftovi with cetuximab (BRAF V600E) and, for MSI-H tumors, Keytruda and Jemperli, plus EGFR exon 19 deletion or L858R. Caris says orders are integrated via EHR at more than 3,100 locations, but the MI Cancer Seek page does not name the EHR systems. A pathology department adopts Sectra for slide management in IDS7, so the two have different buyers.
Sectra, founded in 1978 in Linkoping, describes IDS7 as one viewer for pathology, radiology and genomics images that supports DICOM and vendor-neutral whole-slide images, remote diagnostics and tumor board meetings.
Pathology · Reviewed November 2, 2026
Caris Life Sciences
by Caris Life Sciences · founded 2008
FDA-approved MI Cancer Seek tumor profiling test for oncologists. The GPSai tissue-of-origin AI is a lab service outside that approval.
Sectra Pathology
by Sectra
Digital pathology image management (Sectra IDS7) with a marketplace for third-party AI apps. Sectra does not make the AI.
When to pick each one
Caris Life Sciences
- Founded 2008, listed on NASDAQ as CAI
- Companion diagnostics for Vectibix and Braftovi
- Vendor says EHR ordering at 3,100+ locations
Sectra Pathology
- Sectra describes IDS7 as one viewer for pathology, radiology, genomics
- Supports DICOM and vendor-neutral whole-slide images
- Remote diagnostics and tumor board support
Score
Each row shows points earned of points available under the published rubric.
Caris Life Sciences
65of 100
Sectra Pathology
33of 100
| Dimension | Caris Life Sciences | Sectra Pathology | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 21 / 21 | 0 / 21 | +21 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
Caris Life Sciences
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Sectra Pathology
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Contact form only. |
Evidence
Caris Life Sciences
FDA decisions
P240010 (opens in new tab)PMA2024-11-05
MI Cancer Seek
Peer-reviewed
5 PubMed records name Caris Life Sciences.
- An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins. (opens in new tab)
- Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program. (opens in new tab)
- ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers. (opens in new tab)
Sectra Pathology
FDA decisions
K232208 (opens in new tab)510(k)2024-04-16
Sectra Digital Pathology Module (Version 3.3)
K193054 (opens in new tab)510(k)2020-03-31
Sectra Digital Pathology Module
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Caris Life Sciences | Sectra Pathology |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2008 | n/a |
| HQ | US | SE |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.